Pamisel Secures Site for 3rd Factory... Expands Pharmaceutical Raw Materials Production

[Asia Economy Reporter Hyungsoo Park] Pamicell has made an investment to expand its chemical business division.

On the 15th, Pamicell announced that it had signed a sales contract for a factory site measuring 16,508㎡ (5,000 pyeong) in the Onsan Industrial Complex, Ulsan.

A company official explained, "The site is about 1.75 times larger than the entire area of the existing factory," adding, "We plan to expand the 3rd factory to produce pharmaceutical raw materials such as nucleosides and mPEG, as well as advanced industrial materials."

Pamicell's annual production volume of pharmaceutical raw materials like nucleosides and mPEG is approximately 16 tons, and after the completion of the 3rd factory, production is expected to increase to over 50 tons.

The official said, "We plan to build a large-scale production facility to prepare for the recently increasing demand for nucleosides," and added, "The facility will also be designed to be used for the production of mPEG and advanced materials related to 5G." He continued, "After completion, the annual sales of the chemical business division are expected to continuously increase."

Industry insiders forecast that demand for nucleosides will rise with the activation of RNA therapeutics. Pamicell is currently expanding its 2nd factory, which is scheduled to be completed by the end of June. The company is continuing investments to expand its business, including purchasing land for the 3rd factory and planning additional expansions.

This content was produced with the assistance of AI translation services.